Acute Myeloid Leukemia (AML) lie in precursor tumour-transformed hematopoietic cells, which lead to clonal proliferation and the accumulation of morphologically and functionally immature blast cells [1-5]. AML rarely invades areas other than the bone marrow, but in such instances, the most commonly afflicted organs are soft tissues, lymphatic tissues, and skin [6-9]. In recent years, there has been an ever-growing interest in CNSi during the course of AML (CNSi-AML). Diagnosis rates of CNSi-AML have risen due to the increasing use of flow cytometry to analyze Cerebro-Spinal Fluid (CSF). This technique is more sensitive than cytological examination and has thus enabled more cases of early-stage CNSi-AML to be identified [14,15].]. Secondary involvement of the CNS, in contrast, is the appearance of leukemia cells at this location in the event of relapse or resistance to treatment.Because the CNS is and the literature is thus confined to reporting small adult patient groups [10-13,18-27]. The incidence rate of CNSi-AML at AML diagnosis is estimated at 0.6%-5%, whilst the range at recurrence is 3%-15% [10-14,28].